​
​

Evoke Pharma Ownership 2024 | Who Owns Evoke Pharma Now?

OverviewRevenueFinancialsChartTranscripts

Institutional Ownership

6.09%

Insider Ownership

9.27%

Retail Ownership

84.63%

Institutional Holders

18.00

Evoke Pharma Institutional Shareholders

Institutional Shareholders by % of Total Shares

Name% Total Shares% Total AssetsCurrent SharesChange AmountChange %Market ValueDate
VANGUARD GROUP INC0.95%-29,851--56,717,000Mar 31, 2023
GEODE CAPITAL MANAGEMENT, LLC0.66%-20,894--39,698,000Mar 31, 2023
RENAISSANCE TECHNOLOGIES LLC0.36%-11,17811,178100.00%21,000Mar 31, 2023
TOWER RESEARCH CAPITAL LLC (TRC)0.13%0.00%3,9853,132367.17%8,000Mar 31, 2023
BLACKROCK INC.0.05%-1,473-6,319-81.10%2,799,000Mar 31, 2023
UBS GROUP AG0.04%-1,107--2,103,000Mar 31, 2023
NEWEDGE ADVISORS, LLC0.01%-208--395,000Mar 31, 2023
CONCORD WEALTH PARTNERS0.00%0.00%114114100.00%217,000Mar 31, 2023
LINDBROOK CAPITAL, LLC0.00%-83--158,000Mar 31, 2023
WELLS FARGO & COMPANY/MN0.00%-16--30,000Mar 31, 2023
MORGAN STANLEY----7-100.00%-Mar 31, 2023
PNC FINANCIAL SERVICES GROUP, INC.----32-100.00%-Mar 31, 2023

Evoke Pharma's largest institutional shareholder is VANGUARD GROUP INC, holding 0.95% of the company's total share outstanding, currently valued at $56.72M. The top 10 institutional shareholders own together 2.19% of the company.

Institutional Shareholders by % of Total Assets

Name% Total Shares% Total AssetsCurrent SharesChange AmountChange %Market ValueDate
TOWER RESEARCH CAPITAL LLC (TRC)0.13%0.00%3,9853,132367.17%8,000Mar 31, 2023
CONCORD WEALTH PARTNERS0.00%0.00%114114100.00%217,000Mar 31, 2023
RENAISSANCE TECHNOLOGIES LLC0.36%-11,17811,178100.00%21,000Mar 31, 2023
LINDBROOK CAPITAL, LLC0.00%-83--158,000Mar 31, 2023
GEODE CAPITAL MANAGEMENT, LLC0.66%-20,894--39,698,000Mar 31, 2023
NEWEDGE ADVISORS, LLC0.01%-208--395,000Mar 31, 2023
VANGUARD GROUP INC0.95%-29,851--56,717,000Mar 31, 2023
UBS GROUP AG0.04%-1,107--2,103,000Mar 31, 2023
BLACKROCK INC.0.05%-1,473-6,319-81.10%2,799,000Mar 31, 2023
WELLS FARGO & COMPANY/MN0.00%-16--30,000Mar 31, 2023
MORGAN STANLEY----7-100.00%-Mar 31, 2023
PNC FINANCIAL SERVICES GROUP, INC.----32-100.00%-Mar 31, 2023

The largest Evoke Pharma shareholder by % of total assets is TOWER RESEARCH CAPITAL LLC (TRC). The company owns 3.98K shares of Evoke Pharma (EVOK), representing 0.00% of its total assets.

Institutional Buyers

Name% Total Shares% Total AssetsCurrent SharesChange AmountChange %Market ValueDate
RENAISSANCE TECHNOLOGIES LLC0.36%-11,17811,178100.00%21,000Mar 31, 2023
TOWER RESEARCH CAPITAL LLC (TRC)0.13%0.00%3,9853,132367.17%8,000Mar 31, 2023
CONCORD WEALTH PARTNERS0.00%0.00%114114100.00%217,000Mar 31, 2023
WELLS FARGO & COMPANY/MN0.00%-16--30,000Mar 31, 2023
UBS GROUP AG0.04%-1,107--2,103,000Mar 31, 2023
VANGUARD GROUP INC0.95%-29,851--56,717,000Mar 31, 2023
NEWEDGE ADVISORS, LLC0.01%-208--395,000Mar 31, 2023
GEODE CAPITAL MANAGEMENT, LLC0.66%-20,894--39,698,000Mar 31, 2023
LINDBROOK CAPITAL, LLC0.00%-83--158,000Mar 31, 2023
MORGAN STANLEY----7-100.00%-Mar 31, 2023
PNC FINANCIAL SERVICES GROUP, INC.----32-100.00%-Mar 31, 2023
BLACKROCK INC.0.05%-1,473-6,319-81.10%2,799,000Mar 31, 2023

As of Mar 31 2023, Evoke Pharma's largest institutional buyer is RENAISSANCE TECHNOLOGIES LLC. The company purchased 11.18K stocks of EVOK, valued at $21.00K.

Institutional Sellers

Name% Total Shares% Total AssetsCurrent SharesChange AmountChange %Market ValueDate
BLACKROCK INC.0.05%-1,473-6,319-81.10%2,799,000Mar 31, 2023
PNC FINANCIAL SERVICES GROUP, INC.----32-100.00%-Mar 31, 2023
MORGAN STANLEY----7-100.00%-Mar 31, 2023
LINDBROOK CAPITAL, LLC0.00%-83--158,000Mar 31, 2023
GEODE CAPITAL MANAGEMENT, LLC0.66%-20,894--39,698,000Mar 31, 2023
NEWEDGE ADVISORS, LLC0.01%-208--395,000Mar 31, 2023
VANGUARD GROUP INC0.95%-29,851--56,717,000Mar 31, 2023
UBS GROUP AG0.04%-1,107--2,103,000Mar 31, 2023
WELLS FARGO & COMPANY/MN0.00%-16--30,000Mar 31, 2023
CONCORD WEALTH PARTNERS0.00%0.00%114114100.00%217,000Mar 31, 2023
TOWER RESEARCH CAPITAL LLC (TRC)0.13%0.00%3,9853,132367.17%8,000Mar 31, 2023
RENAISSANCE TECHNOLOGIES LLC0.36%-11,17811,178100.00%21,000Mar 31, 2023

As of Mar 31 2023, Evoke Pharma's biggest institutional seller is BLACKROCK INC.. The company sold -6.32K shares of EVOK, valued at $2.80M.

Institutional New positions

Name% Total Shares% Total AssetsCurrent SharesChange AmountChange %Market ValueDate
RENAISSANCE TECHNOLOGIES LLC0.36%-11,17811,178100.00%21,000Mar 31, 2023
CONCORD WEALTH PARTNERS0.00%0.00%114114100.00%217,000Mar 31, 2023

Evoke Pharma's largest new institutional shareholder by number of shares is RENAISSANCE TECHNOLOGIES LLC, purchased 11.18K shares, valued at $21.00K, as of undefined.

Institutional Sold Out

Name% Total Shares% Total AssetsCurrent SharesChange AmountChange %Market ValueDate
PNC FINANCIAL SERVICES GROUP, INC.----32-100.00%-Mar 31, 2023
MORGAN STANLEY----7-100.00%-Mar 31, 2023

Evoke Pharma's largest sold out institutional shareholder by shares sold is PNC FINANCIAL SERVICES GROUP, INC., sold -32.00 shares, valued at -, as of undefined.

Evoke Pharma Mutual Fund Holders

Name% Total AssetsTotal SharesChange AmountChange %Date
FIDELITY COMMONWEALTH TRUST0.01%30,580--Feb 29, 2024
VANGUARD INDEX FUNDS0.00%1,097,928--Mar 31, 2024
FIDELITY CONCORD STREET TRUST0.00%206,849--Feb 29, 2024
VANGUARD INSTITUTIONAL INDEX FUNDS0.00%17,335--Mar 31, 2024
AdvisorShares Trust0.00%1,604--Mar 28, 2024
SCHWAB CAPITAL TRUST0.00%14,398--Feb 29, 2024
FIDELITY CONCORD STREET TRUST0.00%26,218--Feb 29, 2024
VANGUARD INDEX FUNDS0.00%29,851-29,851-50.00%Mar 31, 2024
USAA MUTUAL FUNDS TRUST0.00%4,382--Jan 31, 2024
iSHARES TRUST0.00%152,321--Mar 31, 2024
EQ ADVISORS TRUST0.00%7,230--Mar 31, 2024
JOHN HANCOCK VARIABLE INSURANCE TRUST0.00%2,608--Mar 31, 2024
DFA INVESTMENT DIMENSIONS GROUP INC0.00%300--Jan 31, 2024
NATIONWIDE MUTUAL FUNDS0.00%31--Jan 31, 2024

Evoke Pharma's largest mutual fund holder by % of total assets is "FIDELITY COMMONWEALTH TRUST", owning 30.58K shares, compromising 0.01% of its total assets.

Evoke Pharma Institutional Ownership Trends

Institutional Holdings Trend

DateHoldingsChange %
31 Mar, 2218-18.18%
31 Dec, 21224.76%
30 Sep, 2121-
30 Jun, 2121-27.59%
31 Mar, 2129-9.38%
31 Dec, 203218.52%
30 Sep, 202758.82%
30 Jun, 201713.33%
31 Mar, 2015-6.25%
31 Dec, 1916-
30 Sep, 1916-
30 Jun, 1916-23.81%
31 Mar, 192116.67%
31 Dec, 1818-10.00%
30 Sep, 18205.26%
30 Jun, 1819-
31 Mar, 1819-24.00%
31 Dec, 172525.00%
30 Sep, 1720-
30 Jun, 1720-13.04%
31 Mar, 172376.92%
31 Dec, 16138.33%
30 Sep, 1612-20.00%
30 Jun, 161536.36%
31 Mar, 1611-21.43%
31 Dec, 151455.56%
30 Sep, 159-25.00%
30 Jun, 15129.09%
31 Mar, 1511-
31 Dec, 1411-
30 Sep, 1411-
30 Jun, 141110.00%
31 Mar, 141042.86%
31 Dec, 137-

As of 31 Mar 22, 18 institutions are holding Evoke Pharma's shares, representing a decrease of -18.18% compared to the previous quarter.

Shares Outstanding Trend

DateShares OutstandingChange %
31 Mar, 221,997,549-2.46%
31 Dec, 212,047,859-51.29%
30 Sep, 214,204,283-6.66%
30 Jun, 214,504,4214.81%
31 Mar, 214,297,63766.20%
31 Dec, 202,585,82741.26%
30 Sep, 201,830,53533.80%
30 Jun, 201,368,157-4.05%
31 Mar, 201,425,8980.02%
31 Dec, 191,425,617-1.79%
30 Sep, 191,451,66916.50%
30 Jun, 191,246,060-26.26%
31 Mar, 191,689,911-46.48%
31 Dec, 183,157,548-1.37%
30 Sep, 183,201,5152.37%
30 Jun, 183,127,51438.71%
31 Mar, 182,254,653-20.08%
31 Dec, 172,821,00136.14%
30 Sep, 172,072,1284.59%
30 Jun, 171,981,1509.99%
31 Mar, 171,801,168223.92%
31 Dec, 16556,045-10.51%
30 Sep, 16621,377-38.56%
30 Jun, 161,011,423161.92%
31 Mar, 16386,158-7.67%
31 Dec, 15418,252-18.11%
30 Sep, 15510,72211.12%
30 Jun, 15459,625-2.65%
31 Mar, 15472,12116.79%
31 Dec, 14404,253-0.14%
30 Sep, 14404,806-1.11%
30 Jun, 14409,365-0.62%
31 Mar, 14411,914164.33%
31 Dec, 13155,832-

Evoke Pharma (EVOK) has 2.00M shares outstanding as of 31 Mar 22, down -2.46% compared to the previous quarter.

Institutional Ownership Trend

DateOwnership %Change %
31 Mar, 226.09%15.05%
31 Dec, 216.36%3.81%
30 Sep, 2112.92%6.68%
30 Jun, 2113.91%7.31%
31 Mar, 2113.79%13.41%
31 Dec, 2010.14%20.70%
30 Sep, 207.00%23.35%
30 Jun, 205.48%16.09%
31 Mar, 205.83%14.27%
31 Dec, 196.39%17.66%
30 Sep, 196.02%20.96%
30 Jun, 195.36%5.73%
31 Mar, 199.67%2.67%
31 Dec, 1819.02%5.44%
30 Sep, 1818.69%5.16%
30 Jun, 1819.04%8.91%
31 Mar, 1814.62%4.34%
31 Dec, 1718.36%10.07%
30 Sep, 1713.50%8.10%
30 Jun, 1712.91%7.28%
31 Mar, 1713.31%65.20%
31 Dec, 164.52%13.19%
30 Sep, 165.85%2.98%
30 Jun, 1614.01%48.28%
31 Mar, 165.39%12.95%
31 Dec, 156.45%10.43%
30 Sep, 157.86%14.37%
30 Jun, 157.40%12.36%
31 Mar, 157.73%17.23%
31 Dec, 146.70%14.99%
30 Sep, 146.69%14.50%
30 Jun, 146.79%14.42%
31 Mar, 146.86%101.83%
31 Dec, 132.60%-

As of 31 Mar 22, Evoke Pharma is held by 6.09% institutional shareholders, representing a 15.05% growth compared to 31 Dec 21.

Institutional Increased Positions Trend

DateIncreased PositionsChange %
31 Mar, 228-
31 Dec, 218-
30 Sep, 218-11.11%
30 Jun, 219-25.00%
31 Mar, 2112-20.00%
31 Dec, 201515.38%
30 Sep, 201330.00%
30 Jun, 2010150.00%
31 Mar, 204-42.86%
31 Dec, 197-12.50%
30 Sep, 19814.29%
30 Jun, 197-12.50%
31 Mar, 19833.33%
31 Dec, 186-14.29%
30 Sep, 18716.67%
30 Jun, 186100.00%
31 Mar, 183-80.00%
31 Dec, 171566.67%
30 Sep, 17950.00%
30 Jun, 176-70.00%
31 Mar, 1720122.22%
31 Dec, 16912.50%
30 Sep, 168-20.00%
30 Jun, 1610400.00%
31 Mar, 162-71.43%
31 Dec, 15775.00%
30 Sep, 154-42.86%
30 Jun, 15716.67%
31 Mar, 156-
31 Dec, 146-
30 Sep, 14620.00%
30 Jun, 145-28.57%
31 Mar, 147-
31 Dec, 137-

8 institutional shareholders have increased their position in EVOK stock as of 31 Mar 22 compared to 8 in the previous quarter (a 0.00% increase).

Institutional Reduced Positions Trend

DateReduced PositionsChange %
31 Mar, 225-
31 Dec, 215-
30 Sep, 21566.67%
30 Jun, 213-25.00%
31 Mar, 214-33.33%
31 Dec, 20650.00%
30 Sep, 204300.00%
30 Jun, 201-50.00%
31 Mar, 202100.00%
31 Dec, 191-50.00%
30 Sep, 192-33.33%
30 Jun, 193-25.00%
31 Mar, 194100.00%
31 Dec, 182100.00%
30 Sep, 181-
30 Jun, 181-80.00%
31 Mar, 18525.00%
31 Dec, 174-
30 Sep, 17--100.00%
30 Jun, 174100.00%
31 Mar, 172-
31 Dec, 16--100.00%
30 Sep, 162-
30 Jun, 162-
31 Mar, 162-
31 Dec, 152-
30 Sep, 15--100.00%
30 Jun, 151-
31 Mar, 151-50.00%
31 Dec, 142-
30 Sep, 142100.00%
30 Jun, 141-66.67%
31 Mar, 143-
31 Dec, 13--

5 institutional shareholders have reduced their position in EVOK stock as of 31 Mar 22 compared to 5 in the previous quarter (a 0.00% increase).

All Institutional Ownership Trend Data

DateHoldingsChange %Shares OutstandingChange %Ownership %Change %Increased PositionsChange %Reduced PositionsChange %
31 Mar, 2218-18.18%1,997,549-2.46%6.09%15.05%8-5-
31 Dec, 21224.76%2,047,859-51.29%6.36%3.81%8-5-
30 Sep, 2121-4,204,283-6.66%12.92%6.68%8-11.11%566.67%
30 Jun, 2121-27.59%4,504,4214.81%13.91%7.31%9-25.00%3-25.00%
31 Mar, 2129-9.38%4,297,63766.20%13.79%13.41%12-20.00%4-33.33%
31 Dec, 203218.52%2,585,82741.26%10.14%20.70%1515.38%650.00%
30 Sep, 202758.82%1,830,53533.80%7.00%23.35%1330.00%4300.00%
30 Jun, 201713.33%1,368,157-4.05%5.48%16.09%10150.00%1-50.00%
31 Mar, 2015-6.25%1,425,8980.02%5.83%14.27%4-42.86%2100.00%
31 Dec, 1916-1,425,617-1.79%6.39%17.66%7-12.50%1-50.00%
30 Sep, 1916-1,451,66916.50%6.02%20.96%814.29%2-33.33%
30 Jun, 1916-23.81%1,246,060-26.26%5.36%5.73%7-12.50%3-25.00%
31 Mar, 192116.67%1,689,911-46.48%9.67%2.67%833.33%4100.00%
31 Dec, 1818-10.00%3,157,548-1.37%19.02%5.44%6-14.29%2100.00%
30 Sep, 18205.26%3,201,5152.37%18.69%5.16%716.67%1-
30 Jun, 1819-3,127,51438.71%19.04%8.91%6100.00%1-80.00%
31 Mar, 1819-24.00%2,254,653-20.08%14.62%4.34%3-80.00%525.00%
31 Dec, 172525.00%2,821,00136.14%18.36%10.07%1566.67%4-
30 Sep, 1720-2,072,1284.59%13.50%8.10%950.00%--100.00%
30 Jun, 1720-13.04%1,981,1509.99%12.91%7.28%6-70.00%4100.00%
31 Mar, 172376.92%1,801,168223.92%13.31%65.20%20122.22%2-
31 Dec, 16138.33%556,045-10.51%4.52%13.19%912.50%--100.00%
30 Sep, 1612-20.00%621,377-38.56%5.85%2.98%8-20.00%2-
30 Jun, 161536.36%1,011,423161.92%14.01%48.28%10400.00%2-
31 Mar, 1611-21.43%386,158-7.67%5.39%12.95%2-71.43%2-
31 Dec, 151455.56%418,252-18.11%6.45%10.43%775.00%2-
30 Sep, 159-25.00%510,72211.12%7.86%14.37%4-42.86%--100.00%
30 Jun, 15129.09%459,625-2.65%7.40%12.36%716.67%1-
31 Mar, 1511-472,12116.79%7.73%17.23%6-1-50.00%
31 Dec, 1411-404,253-0.14%6.70%14.99%6-2-
30 Sep, 1411-404,806-1.11%6.69%14.50%620.00%2100.00%
30 Jun, 141110.00%409,365-0.62%6.79%14.42%5-28.57%1-66.67%
31 Mar, 141042.86%411,914164.33%6.86%101.83%7-3-
31 Dec, 137-155,832-2.60%-7---

Evoke Pharma Insider Shareholders Trades

Open Market Insider Trades

DateNameRelationRoleTransactionBuy/SellSharesPriceValueShares HeldSource

Open Market Insider Buys

DateNameRelationRoleTransactionBuy/SellSharesPriceValueShares HeldSource

Insider Sells

DateNameRelationRoleTransactionBuy/SellSharesPriceValueShares HeldSource
May 30, 2024Kowieski Markofficer Chief Financial OfficerSell16,000$2.09$33.44K-
May 30, 2024Kowieski Markofficer Chief Financial OfficerSell7,500$4.01$30.07K-

All Insider Owners Trades

DateNameRelationRoleTransactionBuy/SellSharesPriceValueShares HeldSource
Aug 08, 2024Kowieski Markofficer Chief Financial OfficerA-AwardBuy17,291$5.27$91.12K17,291
Aug 08, 2024CARLSON MARILYN R.officer Chief Medical OfficerA-AwardBuy17,291$5.27$91.12K17,291
Aug 08, 2024D'Onofrio Matthew Jdirector, officer Chief Executive OfficerA-AwardBuy64,840$5.27$341.71K64,840
May 30, 2024Kowieski Markofficer Chief Financial OfficerBuy---5,000
May 30, 2024Kowieski Markofficer Chief Financial OfficerSell16,000$2.09$33.44K-
May 30, 2024Kowieski Markofficer Chief Financial OfficerSell7,500$4.01$30.07K-
May 24, 2024Hill Malcolm Rdirector-A-AwardBuy14,625$0.45$6.60K14,625
May 24, 2024GARNER CAM Ldirector-A-AwardBuy17,750$0.45$8.01K17,750
May 24, 2024REED VICKIE Sdirector-A-AwardBuy15,000$0.45$6.76K15,000
May 24, 2024WIDDER KENNETH Jdirector-A-AwardBuy14,250$0.45$6.43K14,250
May 24, 2024Brady Todd Cdirector-A-AwardBuy14,625$0.45$6.60K14,625
May 11, 2023WIDDER KENNETH Jdirector-A-AwardBuy14,250$2.12$30.21K14,250
May 11, 2023REED VICKIE Sdirector-A-AwardBuy15,000$2.12$31.80K15,000
May 11, 2023Hill Malcolm Rdirector-A-AwardBuy14,625$2.12$31.00K14,625
May 11, 2023GARNER CAM Ldirector-A-AwardBuy17,750$2.12$37.63K17,750
May 11, 2023Brady Todd Cdirector-A-AwardBuy14,625$2.12$31.00K14,625
Feb 10, 2023Gonyer David Adirector, officer CEOA-AwardBuy30,000$4.01$120.30K30,000
Feb 10, 2023D'Onofrio Matthew Jofficer President & Chief Op. OfficerA-AwardBuy25,000$4.01$100.25K25,000
Feb 10, 2023CARLSON MARILYN R.officer Chief Medical OfficerA-AwardBuy15,000$4.01$60.15K15,000
Apr 28, 2022WIDDER KENNETH Jdirector A-AwardBuy56,000--56,000

The last insider sell of Evoke Pharma's stock was made by Kowieski Mark on May 30 2024, selling 16,000 shares at $2.09 per share (valued at $33.44K).

Evoke Pharma Insider Ownership Trends

All Insider Trades Trend

DateBuySellBuy/Sell Ratio
Q3 20243--
Q2 202452250.00%
Q2 20235--
Q1 20233--
Q2 20229--
Q1 20223--
Q2 20216--
Q1 20213--
Q4 20202633.33%
Q3 20203--
Q2 20206--
Q1 20204--
Q2 20192013153.85%
Q1 20193--
Q3 20186--
Q2 201810--
Q3 20173--
Q2 20177--
Q1 201712--
Q2 201661833.33%

3 total buy trades, and 0 total sell trades (buy/sell ratio of 0%) were made by Evoke Pharma's insiders, as of Q3 2024.

Open Market Insider Trades Trend

DateBuySellBuy/Sell Ratio
Q3 2024---
Q2 2024---
Q2 2023---
Q1 2023---
Q2 2022---
Q1 2022---
Q2 2021---
Q1 2021---
Q4 2020-4-
Q3 2020---
Q2 2020---
Q1 2020---
Q2 2019---
Q1 2019---
Q3 20183--
Q2 2018---
Q3 2017---
Q2 2017---
Q1 20176--
Q2 2016-18-

As of Q3 2024, Insider owners conducted 0 open market buy trades and 0 open market sell trades of Evoke Pharma's stocks.

Evoke Pharma Peer Ownership

TickerCompany
AKANAkanda Corp.
BFRIBiofrontera Inc.
AQSTAquestive Therapeutics, Inc.
GHSIGuardion Health Sciences, Inc.
RGCRegencell Bioscience Holdings Limited
IXHLIncannex Healthcare Limited
SHPHShuttle Pharmaceuticals Holdings, Inc.
DERMJourney Medical Corporation
ACRXTalphera, Inc.
PTPIPetros Pharmaceuticals, Inc.
CPIXCumberland Pharmaceuticals Inc.
PROCProcaps Group S.A.
JUPWSafety Shot Inc
ADMPAdamis Pharmaceuticals Corporation
PRFXPainReform Ltd.
AGRXAgile Therapeutics, Inc.
AVDLAvadel Pharmaceuticals plc
EGRXEagle Pharmaceuticals, Inc.

EVOK Ownership FAQ

Evoke Pharma is owned by institutional shareholders (6.09%), insiders (9.27%), and public (84.63%). The largest institutional shareholder of Evoke Pharma is VANGUARD GROUP INC (0.95% of total shares) and the top mutual fund owner is FIDELITY COMMONWEALTH TRUST (0.01% of total shares).

Evoke Pharma's major institutional shareholders are VANGUARD GROUP INC, GEODE CAPITAL MANAGEMENT, LLC, RENAISSANCE TECHNOLOGIES LLC, TOWER RESEARCH CAPITAL LLC (TRC), and BLACKROCK INC.. The top five shareholders own together 2.14% of the company's share outstanding.

As of Mar 2022, there are 18 institutional shareholders of Evoke Pharma.

VANGUARD GROUP INC owns 29.85K shares of Evoke Pharma, representing 0.95% of the company's total shares outstanding, valued at $56.72M (as of Mar 2023).

As of Mar 2023, GEODE CAPITAL MANAGEMENT, LLC holds 20.89K shares of Evoke Pharma (EVOK), compromising 0.66% of the company, valued at $39.7M.

RENAISSANCE TECHNOLOGIES LLC is the third largest holder of Evoke Pharma. The company owns 11.18K of the company's shares outstanding (worth $21K).